– Bloomberg
Wells Fargo Initiates Coverage On Blueprint Medicines with Underweight Rating, Announces Price Target of $40
Wells Fargo analyst Derek Archila initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Underweight rating and announces Price Target of $40.